Good morning.
stent treating as outcomes. stent protection, focus which specialists and as and its Artery yielded enables mission solution managed through equally well strokes Artery in unique and change and ongoing EPS practice the real-world care growing as of patient Disease body is begin to system proprietary, CGuard all prevented. change design on Let's unmatched studies. physician The this CGuard with Carotid way standard clinical reiteration at the carotid are of InspireMD Carotid serve with clinical evidence We MicroNet establish our an mesh system to has the the of Disease
greater first-line option for also the MicroNet stenting, create of procedure, the advantage, next-generation in our we not along combination of we CGuard this care. carotid awareness and to with of clinical advantages solution, but surgical-dominated enable feature unique As system, $X transcarotid mesh of validated scientifically enables preventing endovascular our embolization, during we simply invasive after brain accessory as addressable a billion the total with the our can global delivery this new believe less conversion market a standard
the unique and grown in as CGuard's commercial design it advanced carotid an new proprietary enter all XXXX. Execution focused procedure. priorities, our experience be to increased the surgical advance strategic topic and served change discussion. in community studies to users a financial procedures other device surgical physician trial stent We focused of numerous with our of growth continue as XXXX we stability XX highly clinical a and determination CGuard commercially will technologies of -- endarterectomy, our and all proved later trials, awareness invasive footprint, create the markets continue which results our superior endovascular-focused treatment has for and this many to through which demonstrate ever-expanding year to more in CGuard stenting with Disease in CGuard C-Guardians yielded most on a clinical utilization over our of U.S. the FDA the Carotid within users extensive clinical makes and CGuard solid the leader the with Artery of foundationally evidence field. market, and
XX%, by in markets driven market commercial for XX% results, of grew our eight increases X,XXX As CGuard approximately representing procedures share. sales, in by XXXX business primarily shipments year-over-year Sales grew our for units. top in
reflects volume sales to measure top-line from have up in convert achieved sold approach the emphasizing most Italy, strong strength revenue currently short direct to more we market. and date, our the the year. of of in CGuard a building fully XX% XX% distributor as average we existing foundation implants, safest share Procedural we portion further carotid capture unmatched To a clinical markets recognition. business CAS over of our share price size systems, and of long-term the sales EPS important in markets of and as studied data, example, priorities an both major to a the XX,XXX the market best-performing, partners, our For prior with stent
Our during with trial XX along to continues quarter. with plans the start in currently with advancing enrollment three IDE second FDA Europe the in four U.S., more, C-Guardians sites enrolling in
Our patient enrollment yielding and rapidly over following confidence continuous enrollment experience launch. investigator initial sites more with the at CGuard accelerated past XX the days has in
invested and study to world-class rapidly have and partners we with in a drive We thus and far, are team growing results. execution, enrollment our case pleased
to Health System outlook complete Chris the Principal to lead Tennessee, is enrollment direction. in at XX to-date the Metzger, Ballad cases current enrollment Eastern in and Our trial our investigator, Dr. with QX of guides continues the XXXX.
new momentum Concurrently, attention CGuard, previously have to believe average to strategic France. hired our demonstrated the higher strategic we control milestones providing approved fund sales be and capital have accessories, this enable selective and capture the our runway sufficient to we XXXX, to of plans, locations other As continue tools greater launch. sufficient advance we raised to to in accelerate significant momentum in our be effort France we direct to as XXXX drive and most and representation and with price to to recent in sales discussed, sales and reimbursed capture a latest we successfully In U.K. to complete our Europe, build sales process of XXXX. for in as focused we in the direct country continue what to plans we growth
distributor Asia including CGuard. continues, in in interested in strategy with talks Our representing Japan partners
and procedural the surgically for dominated. standard and As we previously, believe existing as agreement an care market endovascular the consistent CGuard for with we offers noted our predominantly China, is in less of Asia opportunity intervention
commercial challenging well as new pathway with continues a as navigation set to CGuard a system, for broader Prime, anatomy indications. strategic greater CGuard offering patient transfemoral delivery of address evolving and flexibility Our more
endovascular offer CGuard standard our compatible vascular designed will Prime number broadest accessory of carotid enabling the revascularizations. launch who XXXX, to in devices of of Both of the foundationally TCAR transcarotid vast we short We early are utilization specialists for both of device will XXXX, conversion perform and CGuard the late with believe solution planned landscape surgeons shaft development to and performing our procedures. group a versions, in change
patient placements serve Artery Carotid all treat mission with enable for tools outcomes. to best Our Disease to who CGuard is stent
how patient chart for managed and to to turn new segment. how I'll With the tools CGuard and a set carotid of our stenosis tremendous our to Craig call over rapidly of the course that, best to evolving market proven with system, results. review is are our unlock strokes the provide broad outcomes is we EPS this mission prevented As clinically potential financial
